Mitsubishi Tanabe Dispatched Diabetes Specialists For Launch Of DPP-4 Inhibitor Teneria
This article was originally published in PharmAsia News
Executive Summary
Mitsubishi Tanabe Pharmaceuticals announced Aug. 31 it plans to deploy 1,600 general sales reps and 50 reps specializing in diabetes to provide information on the new DPP-4 inhibitor Teneria it will launch Sept. 10.